source
- CBER Director Karim Mikhail Aims to Restore Stability After Turbulent Leadership ChangesThe FDA's Center for Biologics Evaluation and Research (CBER) is working to regain stability after a period of rapid leadership turnover. Karim Mikhail, who was confirmed as the permanent director…
- TRexBio and Retension raise $161.7M in IPOs as biotech fundraising surge continuesTRexBio and Retension Pharmaceuticals are slated to begin trading on Friday, together raising $161.7 million. Their offerings push the number of biotech IPOs this year to 29, underscoring a continu…